Contineum Therapeutics, Inc. Class A Common Stock
CTNMContineum Therapeutics, Inc. Class A (CTNM) is a biopharmaceutical company focused on developing innovative therapies for rare and serious diseases. The company is dedicated to advancing novel treatment options through cutting-edge research and collaboration, aiming to improve patient outcomes and address unmet medical needs.
Company News
Contineum Therapeutics reported a wider Q2 2025 net loss of $0.62 per share, driven by increased R&D expenses. The company continues developing treatments for pulmonary fibrosis, multiple sclerosis, and depression, with ongoing clinical trials for PIPE-791 and PIPE-307.
The pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players work...
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Lori Lyons-Williams as the new chair of its board of directors, succeeding William Rieflin. Lyons-Williams is an industry veteran with over 20 years of experience in the pharmaceutical and biotech sectors.
This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. Skillsoft posted adjusted loss of $3.09 per share, versus market estimates of $3.27 per share. The company’s quarterly sales came in at $137.540 mil...
